-
Mashup Score: 2
– First CRISPR gene-editing filings to be accepted for review by FDA – – FDA grants Priority Review for severe sickle cell disease (SCD) and Standard Review for transfusion-dependent beta thalassemia (TDT) – – PDUFA target action date of December 8, 2023 , for SCD and March 30, 2024 , for TDT –…
Source: Vertex Pharmaceuticals NewsroomCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 3
The Investor Relations website contains information about Vertex Pharmaceuticals Newsroom’s business for stockholders, potential investors, and financial analysts.
Source: Vertex Pharmaceuticals NewsroomCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 1
The Investor Relations website contains information about Vertex Pharmaceuticals Newsroom’s business for stockholders, potential investors, and financial analysts.
Source: Vertex Pharmaceuticals NewsroomCategories: Healthcare Professionals, Latest HeadlinesTweet
🚨 #GeneTherapy news: @US_FDA accepts @VertexPharma Exa-cel BLA for #SickleCell and #Thalassemia; big shout out to @hfrangoul and @SarahCannonDocs Transplant & Cellular Therapy Program @TriStarHealth - they are among largest enrollers on CLIMB trials https://t.co/34MWXVyfKM